Anjarium Biosciences is a company.
Anjarium Biosciences has raised $60.0M across 1 funding round.
Key people at Anjarium Biosciences.
Anjarium Biosciences has raised $60.0M in total across 1 funding round.
Anjarium Biosciences is a Swiss biotechnology company developing tools and technologies for cell and gene therapy, specializing in synthetic DNA production and non-viral gene therapies.[1][2][3] It provides customizable synthetic DNA constructs that enable researchers and manufacturers to accelerate R&D and production workflows for advanced therapies like AAV vectors, mRNA, and lentiviral applications, addressing limitations of viral-vector approaches with features such as high fidelity, scalability, speed, and re-dosability.[1][2][3][4] The company serves biomedical researchers, pharmaceutical firms, and clinical developers in the genetic medicine sector, solving key bottlenecks in therapy development and delivery to improve efficiency, purity, and patient outcomes.[1][2][5]
With about 25 employees and headquarters in Schlieren, Switzerland, Anjarium has secured investments from firms like Gimv and holds 9 patents in biotechnology and molecular biology, positioning it for growth amid rising demand for non-viral solutions.[2][3]
Founded in 2017 in Schlieren, Switzerland, Anjarium emerged from innovations at the intersection of genetic medicine, synthetic biology, and nanoparticle engineering.[1][3] Joël De Beer, the Founder and Chief Scientific Officer, drives the company's vision for non-viral gene therapies that overcome viral vector limitations like capacity constraints and re-dosing challenges.[3][5] Early traction came from its proprietary DNA-based production platform, enabling targeted synthetic DNA and non-viral vectors for diverse payloads, which attracted investor Gimv and expanded operations to the U.S.[3] Pivotal moments include leadership expansions in 2022, with appointments like Samantha Vieira as COO and Nate Massari as CBO, bolstering operational and business capabilities.[2]
Anjarium stands out in the gene therapy space through:
Anjarium rides the shift from viral to non-viral gene therapies, capitalizing on trends like exosome-based treatments, chronic disease diagnostics (e.g., cancer), and regenerative medicine amid surging funding for genetic medicines.[1][3][4] Timing aligns with evident viral vector shortcomings—such as limited capacity and immunogenicity—driving demand for scalable, re-dosable alternatives in a market where reagents/kits and biomarkers dominate.[1] Favorable forces include academic-pharma collaborations and growth in pharma/biotech end-users, with Anjarium influencing the ecosystem by supplying enabling tools that unlock gene therapy's potential for wider diseases.[1][2][3]
Anjarium is poised to scale its platform with recent executive hires and investor backing, likely advancing its non-viral therapy pipeline toward clinical milestones and partnerships.[2][3] Trends like biomarker-driven diagnostics, vaccine development, and tissue regeneration will propel demand, especially as regulatory clarity emerges in exosomes and gene delivery.[1] Its influence may grow by enabling faster, more accessible therapies, solidifying its role as a key enabler in genetic medicine's evolution from niche to mainstream.[4][5] This positions Anjarium to deliver on its founding promise: empowering breakthroughs for human health through superior DNA technology.[2]
Anjarium Biosciences has raised $60.0M in total across 1 funding round.
Anjarium Biosciences's investors include Abingworth, Sofinnova Investments.
Key people at Anjarium Biosciences.
Anjarium Biosciences has raised $60.0M across 1 funding round. Most recently, it raised $60.0M Series A in September 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2021 | $60.0M Series A | Abingworth, Sofinnova Investments |
